{"id":"chadox1-s-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine uses a replication-deficient chimpanzee adenovirus (ChAdOx1) as a vector to introduce genetic instructions for producing the spike protein of SARS-CoV-2. This triggers both cellular and humoral immune responses, enabling the body to recognize and neutralize the virus upon exposure. The approach leverages established viral vector technology to generate durable immunity without using live virus.","oneSentence":"ChAdOx1-S is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate adaptive immune responses against COVID-19.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:29.074Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT05710783","phase":"PHASE2, PHASE3","title":"Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster.","status":"COMPLETED","sponsor":"Laboratorio Avi-Mex, S.A. de C.V.","startDate":"2022-11-09","conditions":"SARS-CoV-2 Infection","enrollment":4065},{"nctId":"NCT05205746","phase":"PHASE2","title":"Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence","status":"COMPLETED","sponsor":"Laboratorio Avi-Mex, S.A. de C.V.","startDate":"2021-11-23","conditions":"SARS CoV 2 Infection","enrollment":158},{"nctId":"NCT05571735","phase":"","title":"Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2023-04-15","conditions":"Covid-19 Pandemics, Tuberculosis","enrollment":133},{"nctId":"NCT04894435","phase":"PHASE2","title":"Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2021-05-20","conditions":"COVID-19","enrollment":669},{"nctId":"NCT05697705","phase":"","title":"Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-22","conditions":"COVID-19","enrollment":188814085},{"nctId":"NCT05501522","phase":"PHASE3","title":"Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2022-12-09","conditions":"COVID-19","enrollment":840},{"nctId":"NCT04760132","phase":"PHASE4","title":"National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE)","status":"COMPLETED","sponsor":"Jens D Lundgren, MD","startDate":"2021-02-08","conditions":"SARS-CoV Infection","enrollment":7600},{"nctId":"NCT05007951","phase":"PHASE3","title":"Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2021-08-30","conditions":"Covid19","enrollment":4036},{"nctId":"NCT05387317","phase":"PHASE3","title":"Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2024-04","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05543356","phase":"PHASE3","title":"COVID-19 Fourth Dose Study in Australia","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05343871","phase":"PHASE4","title":"Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial","status":"COMPLETED","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2022-07-05","conditions":"COVID-19","enrollment":2354},{"nctId":"NCT06189040","phase":"PHASE4","title":"Immunogenicity After COVID-19 Vaccines in Adapted Schedules","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2021-05-26","conditions":"Coronavirus Disease 2019, COVID-19","enrollment":580},{"nctId":"NCT05052307","phase":"","title":"A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil","status":"COMPLETED","sponsor":"Hospital Moinhos de Vento","startDate":"2021-11-03","conditions":"Covid19","enrollment":4574},{"nctId":"NCT04742842","phase":"PHASE1","title":"The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers","status":"COMPLETED","sponsor":"University of Sydney","startDate":"2021-06-21","conditions":"SARS-CoV2 COVID-19","enrollment":68},{"nctId":"NCT04914832","phase":"PHASE4","title":"Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death","status":"COMPLETED","sponsor":"Shabir Madhi","startDate":"2021-08-30","conditions":"COVID-19, Pneumonia, Viral","enrollment":75012},{"nctId":"NCT05188677","phase":"PHASE3","title":"Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults","status":"COMPLETED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2022-06-13","conditions":"COVID-19","enrollment":1831},{"nctId":"NCT05710289","phase":"","title":"A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.","status":"WITHDRAWN","sponsor":"SK Bioscience Co., Ltd.","startDate":"2023-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05272605","phase":"PHASE1","title":"Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"University of Melbourne","startDate":"2022-04-05","conditions":"SARS-CoV-2","enrollment":76},{"nctId":"NCT04864561","phase":"PHASE3","title":"COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2021-04-26","conditions":"SARS-CoV-2 Virus Infection","enrollment":4034},{"nctId":"NCT05197153","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2022-01-22","conditions":"COVID-19 Vaccine","enrollment":804},{"nctId":"NCT05228912","phase":"","title":"Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.","status":"COMPLETED","sponsor":"Hospital Clinica Nova","startDate":"2021-02-26","conditions":"Vaccine Adverse Reaction, COVID-19, Vaccine Reaction","enrollment":1870},{"nctId":"NCT05175950","phase":"PHASE2","title":"Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2022-01-24","conditions":"COVID-19 (Healthy Volunteers)","enrollment":770},{"nctId":"NCT05076227","phase":"","title":"Effect of Different SARS-CoV-2 Vaccine Schedules and Vaccination Intervals on Reactogenicity and Humoral Immunogenicity","status":"COMPLETED","sponsor":"Serge Thal","startDate":"2021-01-30","conditions":"SARS-CoV2 Infection, Immunisation Reaction, Antibody Hypersensitivity","enrollment":1206},{"nctId":"NCT04760730","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2021-07-13","conditions":"COVID-19","enrollment":100},{"nctId":"NCT05293665","phase":"PHASE3","title":"Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine","status":"UNKNOWN","sponsor":"Vaxxinity, Inc.","startDate":"2022-03-16","conditions":"COVID-19 Vaccines","enrollment":944},{"nctId":"NCT05534035","phase":"PHASE3","title":"Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and Older","status":"UNKNOWN","sponsor":"Everest Medicines (Singapore) Pte. Ltd.","startDate":"2023-02-03","conditions":"SARS-CoV-2 Infection","enrollment":450},{"nctId":"NCT05049226","phase":"PHASE2","title":"Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2021-09-24","conditions":"COVID-19 Infection, COVID-19 VACCINE","enrollment":1250},{"nctId":"NCT04684446","phase":"PHASE1, PHASE2","title":"Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2021-09-15","conditions":"COVID-19","enrollment":100},{"nctId":"NCT04686773","phase":"PHASE2","title":"Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2021-03-05","conditions":"COVID-19","enrollment":100},{"nctId":"NCT05289206","phase":"NA","title":"Immune Response of an Interchangeable Booster Vaccine Against COVID-19 Among Individuals With Risk Factors for Severity","status":"UNKNOWN","sponsor":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","startDate":"2021-09-30","conditions":"Comorbidities and Coexisting Conditions, Healthy","enrollment":4446},{"nctId":"NCT05324319","phase":"PHASE2","title":"Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2021-06-15","conditions":"COVID-19","enrollment":200},{"nctId":"NCT05087368","phase":"PHASE2","title":"Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19)","status":"UNKNOWN","sponsor":"D'Or Institute for Research and Education","startDate":"2021-12-01","conditions":"Covid19","enrollment":520},{"nctId":"NCT04540393","phase":"PHASE3","title":"AZD1222 Vaccine for the Prevention of COVID-19","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2020-09-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04907331","phase":"PHASE2","title":"Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2","status":"UNKNOWN","sponsor":"Medical University Innsbruck","startDate":"2021-05-10","conditions":"SARS-CoV2 Infection","enrollment":3000},{"nctId":"NCT05027672","phase":"PHASE2","title":"Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines.","status":"UNKNOWN","sponsor":"Ministerio de Salud de Ciudad Autónoma de Buenos Aires","startDate":"2021-07-30","conditions":"COVID-19 Vaccines","enrollment":348},{"nctId":"NCT04962906","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes","status":"COMPLETED","sponsor":"Ministerio de Salud de Ciudad Autónoma de Buenos Aires","startDate":"2021-07-05","conditions":"COVID-19 Vaccines","enrollment":192},{"nctId":"NCT04983537","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes in an Elderly Population","status":"UNKNOWN","sponsor":"Ministerio de Salud de Ciudad Autónoma de Buenos Aires","startDate":"2021-07-26","conditions":"COVID-19 Vaccines","enrollment":120},{"nctId":"NCT04170829","phase":"PHASE1","title":"A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002)","status":"COMPLETED","sponsor":"King Abdullah International Medical Research Center","startDate":"2019-12-17","conditions":"Middle East Respiratory Syndrome Coronavirus","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":43,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ChAdOx1-S vaccine","genericName":"ChAdOx1-S vaccine","companyName":"Vaxxinity, Inc.","companyId":"vaxxinity-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"ChAdOx1-S is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate adaptive immune responses against COVID-19. Used for COVID-19 prevention (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}